Content area
Full Text
Zymeworks must be spending a fortune on pens as it inks yet another deal, this time with Johnson & Johnson’s biotech unit.
Under the deal, Janssen gets its hands on worldwide, royalty-bearing license to research, develop, and sell up to six bispecific antibodies directed to Janssen therapeutic targets using Zymeworks’ Azymetric and Efect platforms.
For its side, Zymeworks gets a tidy fee of $50 million upfront, and if all goes well can look forward to $282 million in development milestones. The big prize, however, is the potential $1.12 billion in sales payments, although this would...